Claims

1. An anti-oncostatin M receptor (OSMR) antibody, comprising:

a light chain variable domain comprising a light chain complementary-determining region 1 (LCDR1) defined by SEQ ID NO:31, a light chain complementary-determining region 2 (LCDR2) defined by SEQ ID NO:34, and a light chain complementary-determining region 3 (LCDR3) defined by SEQ ID NO:37; and

a heavy chain variable domain comprising a heavy chain complementary-determining region 1 (HCDR1) defined by SEQ ID NO:13, a heavy chain complementary-determining region 2 (HCDR2) defined by SEQ ID NO:16, and a heavy chain complementary-determining region 3 (HCDR3) defined by SEQ ID NO:19.

2. The anti-OSMR antibody of claim 1, wherein the light chain variable domain has the amino acid sequence set forth in SEQ ID NO:28.

3. The anti-OSMR antibody of claim 1, wherein the heavy chain variable domain has the amino acid sequence set forth in SEQ ID NO:54.

4. The anti-OSMR antibody of claim 1, wherein:
the light chain variable domain has the amino acid sequence set forth in SEQ ID NO:28; and
the heavy chain variable domain has the amino acid sequence set forth in SEQ ID NO:54.

5. The anti-OSMR antibody of claim 1, wherein the light chain of the antibody comprises the amino acid sequence set forth in SEQ ID NO:25.

6. The anti-OSMR antibody of claim 1, wherein the antibody is a monoclonal antibody.

7. The anti-OSMR antibody of claim 6, wherein the antibody is a human antibody.

8. The anti-OSMR antibody of claim 1, wherein the antibody inhibits binding of human oncostatin M (OSM) or human interleukin 31 to human OSMR.

9. The anti-OSMR antibody of claim 1, wherein the antibody reduces human OSM-mediated or human interleukin 31-mediated OSMR signaling in human OSMR-expressing cells.

10. The anti-OSMR antibody of claim 4, wherein the antibody is a monoclonal antibody.

11. The anti-OSMR antibody of claim 10, wherein the antibody is a human antibody.

12. The anti-OSMR antibody of claim 4, wherein the light chain of the antibody comprises the amino acid sequence set forth in SEQ ID NO:25.

13. The anti-OSMR antibody of claim 4, wherein the antibody inhibits binding of human OSM or human interleukin 31 to human OSMR.

14. The anti-OSMR antibody of claim 4, wherein the antibody reduces human OSM-mediated or human interleukin 31-mediated OSMR signaling in human OSMR-expressing cells.

15. A pharmaceutical composition comprising the anti-OSMR antibody of claim 1.

16. A pharmaceutical composition comprising the anti-OSMR antibody of claim 4.